1. 1389PImpact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors. (23rd October 2018) Authors: Fucà, G; Poggi, M; Galli, G; Imbimbo, M; Lo Russo, G; Signorelli, D; Vitali, M; Ganzinelli, M; Zilembo, N; de Braud, F; Garassino, M C; Proto, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1419PBasal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer. (23rd October 2018) Authors: Galli, G; Poggi, M; Fucà, G; Lo Russo, G; Proto, C; Signorelli, D; Vitali, M; Ganzinelli, M; Zilembo, N; de Braud, F; Garassino, M C; Imbimbo, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018) Authors: Rodriguez Abreu, D; Garassino, M C; Esteban, E; Speranza, G; Felip, E; Domine, M; Hochmair, M J; Powell, S F; Cheng, S Y-S; Bischoff, H; Peled, N; Hui, R; Reck, M; Garon, E B; Boyer, M; Grossi, F; Jennens, R; Yang, J; Pietanza, M C; Gadgeel, S M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1466PEffects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer. (23rd October 2018) Authors: Galli, G; Poggi, M; Fucà1, G; Imbimbo, M; Proto, C; Signorelli, D; Vitali, M; Zilembo, N; Ganzinelli, M; de Braud, F; Garassino, M C; Lo Russo, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 53PImmune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme. (17th December 2018) Authors: Baldini, E; Lunghi, A; Cortesi, E; Turci, D; Garassino, M C; Stati, V; Ardizzoni, A; Ricciuti, B; Frassoldati, A; Romano, G; Illiano, A; Verderame, F; Fasola, G; Marchetti, P; Pinto, C; Carteni, G; Scotti, V; Tibaldi, C; Fioretto, L; Giannarelli, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. (15th December 2019) Authors: Gadgeel, S; Rodriguez-Abreu, D; Felip, E; Esteban, E; Speranza, G; Reck, M; Hui, R; Boyer, M; Garon, E B; Horinouchi, H; Cristescu, R; Aurora-Garg, D; Lunceford, J; Kobie, J; Ayers, M; Piperdi, B; Pietanza, M C; Garassino, M C Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗